Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://puff-la-disposable285924.judgeblog.com/61486205/novo-nordisk-s-retatrutide-australia-a-potential-solution-for-obesity-treatment